USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
08 Nov 2022 | 03:45 PM GMT

How Can DTx Companies Monetize the RWD They Generate?

Anchored by:

Philip Russmeyer
Founder and CEO
FITFILE

Participants:

Philip Russmeyer Founder and CEOFitfile
Philip Russmeyer
Founder and CEOFitfile
Amanda Goltz US Lead, Healthcare Startups and VCAWS
Amanda Goltz
US Lead, Healthcare Startups and VCAWS
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Amanda Woodward Insights ManagerTwill
Amanda Woodward
Insights ManagerTwill
Elaina Bolinger Senior Insights ManagerBayer AG
Elaina Bolinger
Senior Insights ManagerBayer AG
HV
Henri Viertolahti Deputy GMKaiku Health
HV
Henri Viertolahti
Deputy GMKaiku Health
Mark Goodyear Co-Founder and Chairmancarecircle
Mark Goodyear
Co-Founder and Chairmancarecircle
Richie Bavasso PresidentPneumoWave
Richie Bavasso
PresidentPneumoWave
Zsuzsanna Varga Global Digital Asset and Programs LeadBiogen Idec
Zsuzsanna Varga
Global Digital Asset and Programs LeadBiogen Idec

About this Meeting

Real-World Data (RWD) can be highly valuable for many stakeholders in healthcare, such as pharma, MedTech, payers, or hospitals. RWD could potentially help in drug and medical device label extension, discovery, identification of unmet needs, stratification of populations, and identification of high-risk patients, among others.  

While RWD can come from many sources, DTx solutions are proving to be excellent data-gathering tools. How can DTx companies monetize the RWD they generate? Can they build a business model around this? Join other senior leaders in this session to discuss the following: 

  • Is selling this anonymized data a sustainable revenue stream for DTx companies? How much revenue can DTx make from this business model? 
  • How can DTx companies combine their RWD with other data sets to build richer profiles that are easier to monetize? How can DTx companies work together with other organizations to generate and standardize data before selling it? 
  • Buyers’ quality standards for DTx-generated RWD: do DTx companies meet these standards? Do the potential buyers (like pharma, MedTech, payers, etc.) prefer to collect the data using their own capabilities? 
  • Challenges and barriers when selling RWD: convincing of the value, lack of trust in DTx-generated data, privacy concerns, compliance, access to raw data, ownership of the data, regulations, etc.? 
  • Are stakeholders like pharma or payers currently using RWD? What data points can DTx companies easily sell?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.